Our multiplex PCR and mass spectrometry pharmacogenetics assay can detect single nucleotide polymorphisms, internal deletion variants, and copy number variants for several genes with pharmacogenetic implications.
Acceptable sample types include whole blood samples and buccal (cheek) swabs.
This type of testing is performed to aid in a healthcare provider’s determination of effective drug therapies and reduce the patient’s risk of adverse effects. Based on a patient’s genetic makeup, their test results will outline how their DNA will affect drug metabolism.
Additionally, our report includes a summary of patient-specific indications of drug-to-drug interaction to further optimize medication therapies.
ADHD/Neurology Panel: Antiaddictives, anti-ADHD agents, antidepressants, anticonvulsants, antidementia agents, antipsychotics, benzodiazepines and other neurological agents
Cardiology Panel: Angiotensin II receptor antagonists, antianginal agents, antiarrhythmics, anticoagulants, antiplatelets, beta-blockers, diuretics, statins and others
Gastrointestinal Panel: Antiemetics, proton-pump inhibitors
Mental Health/Psychiatry Panel: Antiaddictives, anti-ADHD agents, antidepressants, anticonvulsants, antidementia agents, anti-psychotics, benzodiazepines
Orthopedic Panel: Anti-hyperuricemias and anti-gout agents, immunodulators
Pain Management Panel: Fibromyalgia agents, muscle relaxants, NSAIDs, opioids
Urological Panel: 5 alpha reductase inhibitors and alpha-blockers for benign prostatic hyperplasia, antispasmodics for overactive bladder, phosphodiesterase inhibitors for erectile dysfunction
Comprehensive Panel: All of the above